6: Peptalk Week in Review — October 16, 2026
Unable to add items
Add to basket failed.
Add to wishlist failed.
Failed to remove from Wish List.
Adding to library failed
Unable to follow podcast
Unable to unfollow podcast
-
Narrated by:
-
By:
This week the biggest story isn't a trial readout — it's the economy reshaping itself around GLP-1s.
Jake and Cynthia unpack Gallup's new numbers (15% of US adults have tried a GLP-1 for weight loss, up from 3% two years ago), the Cornell grocery-receipts study (household spending down 5.3%, savory snacks down 10%), and the BCG survey (active users spending 11% more on high-protein foods). Plus the industry response: Olive Garden's Lighter Portions menu, Nestlé's GLP-1 nutrition line, and Walmart covering Ozempic and Mounjaro at zero cost for employees with type 2 diabetes in 2027.
Also: a Blood Cancer Journal study of 140,000 matched patients finds no blood-cancer risk signal from GLP-1s.
Semaglutide extends lifespan 12% in mice (Nature); Pharma's GLP-1 brain-drug pipeline heats up with Lilly's Brenipatide for alcohol use disorder; and the amylin wave builds with Petrelintide (10.7%), Survodutide (13.1%), and Trevogrumab's 70% muscle-loss prevention.
For research and informational purposes only — not medical advice.
**Sources:**
- Gallup — GLP-1 usage reaches new high (15% ever-used, 11% current; May–June 2026 survey): https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx
- Medical Xpress — Cornell/Journal of Marketing Research grocery spending study (Dec 2025): https://medicalxpress.com/news/2025-12-ozempic-foods-americans-buy.html
- Green Queen — BCG GLP-1 food consumption survey (+11% protein, +15% fruit/veg): https://www.greenqueen.com.hk/boston-consulting-group-glp-1-food-consumption-spending-protein-fiber-survey/
- Yahoo Lifestyle — Olive Garden "Lighter Portions" menu, GLP-1 users cited (Oct 13, 2026): https://www.yahoo.com/lifestyle/articles/restaurant-menus-getting-smaller-glp-160004125.html
- Mexico Business News — Novo Nordisk CEO on food industry rethink (Oct 12, 2026): https://mexicobusiness.news/health/news/glp-1-drugs-push-food-industry-rethink-portions-products
- WebProNews — GLP-1 drugs shrink appetites; food company earnings calls (Oct 12, 2026): https://www.webpronews.com/glp-1-drugs-shrink-appetites-and-grocery-bills-pharma-giants-reap-billions-while-snack-makers-scramble/
- Food Navigator — Nestlé developing GLP-1 nutrition products (Oct 8, 2026): https://www.foodnavigator.com/Article/2026/10/08/how-glp-1-weight-loss-drugs-are-reshaping-food-and-beverage-innovation/
- CNBC — Walmart $0 GLP-1s for T2D employees in 2027 (Oct 13, 2026): https://www.cnbc.com/2026/10/13/walmart-glp-1s-inhalers-employee-benefits.html
- Nature / Blood Cancer Journal — GLP-1RAs and hematologic malignancy risk, TriNetX matched cohort (Oct 12, 2026): https://www.nature.com/articles/s41408-026-01618-4
- CNN — Semaglutide extends lifespan in older mice, Nature study (Oct 13, 2026): https://www.cnn.com/2026/10/13/health/glp-1-drugs-anti-aging
- UC Berkeley — GLP-1 treatment extends lifespan in older healthy mice (Sept 2026): https://vcresearch.berkeley.edu/news/glp-1-treatment-extends-lifespan-older-healthy-mice.
- Nature — Pharma's GLP-1 brain-drug pipeline: brenipatide, KP405, Baseline Therapeutics (Oct 13, 2026): https://www.nature.com/articles/d41586-026-03252-3
- Pharmacy Times — Petrelintide Phase 2 ZUPREME-1: up to 10.7% at 42 weeks (Oct 6, 2026): https://www.pharmacytimes.com/view/petrelintide-yields-up-to-10-7-weight-loss-with-mild-gi-effects
- GlobeNewswire — Zealand Pharma: Survodutide SYNCHRONIZE-2 up to 13.1% at 76 weeks (Oct 1, 2026): https://www.globenewswire.com/news-release/2026/10/01/3372565/0/en/zealand-pharma-announces-boehringer-ingelheim-s-survodutide-achieves-up-to-13-1-weight-loss-in-new-phase-iii-trial-alongside-significant-improvements-in-glycemic-control-in-people-.html
- GlobeNewswire — Regeneron: Trevogrumab COURAGE prevents 70% of GLP-1 muscle loss (Oct 1, 2026): https://www.globenewswire.com/news-release/2026/10/01/3373155/0/en/phase-2-courage-trial-confirms-trevogrumab-prevents-lean-mass-and-muscle-loss-during-glp-1-receptor-agonist-induced-weight-loss.html
A Spoke-Media production:
https://www.spoke-media.com